Bios­plice search­es for a path for­ward af­ter os­teoarthri­tis drug fails late-stage study

Bios­plice’s os­teoarthri­tis drug has failed a Phase 3 clin­i­cal tri­al, ac­cord­ing to the drug­mak­er, sig­nif­i­cant­ly cloud­ing the drug’s chances of ap­proval and the fu­ture of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER